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Abbreviations
 ADR: Adverse drug reaction

 IRB: Institutional review board

 AW: Alcohol withdrawal

 IV: Intravenous

 BZD: Benzodiazepine

 LOS: Length of stay

 CIWA-Ar: Clinical Institute

 MINDS: Minnesota Detoxification

Withdrawal Assessment for Alcohol, Scale
revised
 STT: Symptom-triggered therapy
 GABA: Gamma-aminobutyric acid
 ICU: Intensive care unit
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Objective
 Discuss the outcomes of a fixed-dose protocol for the management of

AW in a community hospital

4

Background
 In the United States, 2 to 7% of heavy alcohol users admitted to the

hospital for general medical care will develop severe AW
 The most dangerous complications of AW are delirium tremens and
seizures
 Benzodiazepines are considered first-line therapy

o Alcohol is a central nervous system depressant which acts by modulation of

GABA and glutamate activity
o BZDs modulate binding of GABA to its receptor, increasing chloride ion influx
and causing an inhibitory effect similar to alcohol
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The Journal of the American Medical Association. 2018; 320(8), 825-833.
The Journal of Human Pharmacology and Drug Therapy. 2016; 36(7), 797-822.

Fixed-Dose versus STT
 Fixed-dose
 STT
o Historically has been used to
o BZDs are only administered when
manage AW
severity of symptoms necessitate,
according to AW scale scoring
o BZDs are given at regular intervals
o Evidence shows that STT results in:
o Additional doses are given as
 Lower doses of BZDs
needed depending on severity of the
 Shorter BZD duration
symptoms according to AW scale
 Decreased rate of severe AW
scoring
 Shorter duration of AW syndrome
 Decreased complications
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The Journal of Human Pharmacology and Drug Therapy. 2018; 38(7), 701-713.

Purpose
 The purpose of this study was to evaluate the current BZD fixed-dose

protocol and outline the transition to STT in the ICU
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Study Design
 Single center, IRB approved,

 Inclusion
retrospective chart review of patients o Admitted to an ICU
treated for AW with a fixed-dose BZD o Treatment for AW
protocol
o Use of BZDs

 Study period: November 2017-

December 2019

 Exclusion
o Age < 18 years
o Pregnancy
o Allergy to BZD
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Screening
A total of 90 patients
were reviewed
Excluded patients
• 39 BZD use for anxiety
• 5 BZD use as needed
46 patients met
inclusion criteria
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Outcomes
 Primary outcomes
o Amount of BZD(s) used

• Chlordiazepoxide daily mg dose

o Duration of BZD therapy
• Days of BZD use
o Time to symptom control
• Total days; beginning of symptoms to
when symptoms were controlled

 Secondary outcomes
o BZD-related adverse effects

• Any BZD-related ADR such as

somnolence, drowsiness,
hypotension, or unresponsiveness
• Reported by the nurse or physician

o LOS in the ICU
• Days spent in the ICU
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Statistical Methods
 Descriptive statistics
o Mean

• Duration of therapy
• Time to symptom control

o Median
• Daily BZD use
• LOS in the ICU
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Results: Primary Outcomes
BZD Use

 Daily BZD(s) used:
o 75 mg daily
 Duration of BZD therapy:
o 5.4 days
 Time to symptom control:
o 4.25 days

9%

26%

65%
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Asymptomatic

After symptoms were controlled

Similar duration of symptoms

Results: Secondary Outcomes
BZD ADRs
25 (54%)
25

21 (46%)

20

 BZD-related adverse effects
o Approximately 42% of the patients
who experienced an ADR received
BZDs while asymptomatic or after
symptoms were controlled
 LOS in the ICU
o Median: 3 days
o Majority of patients were
transferred to the floors

15

10

5

ADR Occurred

No ADR
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Additional Findings
 Only 21% of the prescribers used the AW PowerPlan
 Approximately 30% of patients had a CIWA-Ar score documented
o For patients with a documented CIWA-Ar score, most had low scores for
which treatment was not indicated
o The use of CIWA-Ar did not necessarily correlate with the use of the
PowerPlan
o In patients with a CIWA-Ar score, reassessment of the score was not
conducted
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Conclusions
 The fixed-dose protocol led to patients receiving unnecessary treatment for

AW
 Duration of BZD therapy was longer than time to symptom control,
exposing patients to an extra day of unnecessary therapy
o A large percentage of these patients experienced an ADR

 Areas for improvement for appropriate patient monitoring were identified,

given the lack of use of the AW PowerPlan and poor documentation of
CIWA-Ar scores
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Limitations
 Retrospective chart review
 Small sample size
 Information assessed based on documentation
 Multiple sedative medications utilized
 Challenging to assess ADRs in intubated patients
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Transition to STT
 Patients with AW will be treated using STT
 BZD of choice will be lorazepam oral or IV
 BZD will be administered based on a scale score (CIWA-Ar or MINDS)
 Score severity will determine BZD dose and monitoring parameters
o Monitoring will be conducted by nurses
o Parameters will be pre-determined to ensure proper escalation and deescalation of therapy
 Education will be provided to physicians, nurses, and pharmacists
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Assessment Question
 Which of the following outcomes is associated with fixed-dose

benzodiazepine protocols?
A.
B.
C.
D.

Increased benzodiazepine use
Shorter duration of benzodiazepine use
Less sedation
Decreased length of stay
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Assessment Answer
 Which of the following outcomes is associated with fixed-dose

benzodiazepine protocols?
A.
B.
C.
D.

Increased benzodiazepine use
Shorter duration of benzodiazepine use
Less sedation
Decreased length of stay
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